scholarly journals A high frequency of CD8+CD28- T-suppressor cells contributes to maintaining stable graft function and reducing immunosuppressant dosage after liver transplantation

2018 ◽  
Vol 15 (9) ◽  
pp. 892-899 ◽  
Author(s):  
Lei Geng ◽  
Jingfeng Liu ◽  
Junjie Huang ◽  
Bingyi Lin ◽  
Songfeng Yu ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
High Frequency ◽  
Graft Function ◽  
Suppressor Cells ◽  
T Suppressor Cells

Allospecific T-suppressor cells in liver transplantation

2001 ◽  
Vol 33 (1-2) ◽  
pp. 1381-1383 ◽  
Author(s):  
E.R Molajoni ◽  
P Cinti ◽  
E Ho ◽  
B Evangelista ◽  
M.T Lonardo ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Suppressor Cells ◽  
T Suppressor Cells

scholarly journals Discontinuation of Passive Immunization Is Safe after Liver Transplantation for Combined HBV/HDV Infection

Viruses ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 904
Author(s):  
Ramin Raul Ossami Saidy ◽  
Irina Sud ◽  
Franziska Eurich ◽  
Mustafa Aydin ◽  
Maximilian Paul Postel ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Overall Survival ◽  
Hepatitis B ◽  
Graft Function ◽  
Passive Immunization ◽  
Standard Regimen ◽  
Long Term Follow Up ◽  
Hdv Infection ◽  
End Stage

Patients after LT due to combined HBV/HDV infection are considered to be high-risk patients for recurrence of hepatitis B and D. To date, life-long prophylaxis with hepatitis B immunoglobulin (HBIG) and replication control with nucleos(t)ide analogs (NA) remains standard. We examined the course of 36 patients that underwent liver transplantation from 1989 to 2020 for combined HBV/HDV-associated end-stage liver disease in this retrospective study. Seventeen patients eventually discontinued HBIG therapy for various reasons. Their graft function, histopathological findings from routine liver biopsies and overall survival were compared with those that received an unaltered NA-based standard regimen combined with HBIG. The median follow-up was 204 and 227 months, respectively. The recurrence of HBV was 25% and did not differ between the groups of standard reinfection prophylaxis NA/HBIG (21.1%) and HBIG discontinuation (29.4%); (p = 0.56). No significant differences were found regarding the clinical course or histopathological aspects of liver tissue damage (inflammation, fibrosis, steatosis) between these two groups. Overall, and adjusted survival did not differ between the groups. Discontinuation of HBIG in stable patients after LT for combined HBV/HDV did not lead to impaired overall survival or higher recurrence rate of HBV/HDV infection in this long-term follow-up. Therefore, the recommendation of the duration of HBG administration must be questioned. The earliest time of discontinuation remains unclear.

scholarly journals Donor des-gamma-carboxy prothrombin positivity is a risk factor for poor early graft function in liver transplantation

1998 ◽  
Vol 11 (2) ◽  
pp. 143-146 ◽  
Author(s):  
Taketoshi Suehiro ◽  
Peter Boros ◽  
Sukru Emre ◽  
Patricia A. Sheiner ◽  
Stephen Guy ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Risk Factor ◽  
Graft Function ◽  
Early Graft

Indocyanine green clearance as a marker of graft function in liver transplantation

1999 ◽  
Vol 31 (6) ◽  
pp. 2447-2448 ◽  
Author(s):  
J. Igea ◽  
J. Nuño ◽  
P. López-Hervás ◽  
Y. Quijano ◽  
A. Honrubia ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Indocyanine Green ◽  
Graft Function ◽  
Indocyanine Green Clearance

Manipulation of autoimmune diseases with T-suppressor cells: lessons from experimental SLE and EAE

1993 ◽  
Vol 36 (2) ◽  
pp. 109-116 ◽  
Author(s):  
Yehuda Shoenfeld ◽  
Miri Blank ◽  
Rina Aharoni ◽  
Dvora Teitelbaum ◽  
Ruth Arnon
Keyword(s):  
Autoimmune Diseases ◽  
Suppressor Cells ◽  
T Suppressor Cells
Sign in / Sign up

Export Citation Format

Share Document